A Phase 3 interventional study of Acetaminophen 250 mg and Aspirin 250 mg and Placebo in Acute Migraine, sponsored by Novartis. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-11.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing acetaminophen in Migraine Disorders — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Migraine Disorders.
Among the 15 studies testing acetaminophen in Migraine Disorders, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 5th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →1 of the 15 studies testing acetaminophen in Migraine Disorders is open now, in 1 country. Recruiting first, the newest first:
University of Monastir · Sites in Tunisia
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 1998; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 900 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 200 across the 15 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 15 have an industry lead sponsor. The 9 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
15 studies in Migraine Disorders by Novartis: none open now, none under way, none of them phase 3. Of 13 finished, 7 (54%) have results posted.
Among the 15 studies in Migraine Disorders by Novartis, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is one of 5 in phase 3, and was the 5th registered.
Novartis’s Migraine Disorders studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing acetaminophen in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 15 in Migraine Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Subjects eligible for inclusion in this study must not fulfill any of the following criteria:
Headache symptoms which may be due to or aggravated by:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
Drug: Placebo
2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
Drug: Acetaminophen 250 mg and Aspirin 250 mg
Drug page: Acetaminophen
2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
Number of Subjects Who Are Pain Free at the 2-hour Assessment
Number of subjects who are pain free at the 2-hour assessment
Time frame: 2 hours
Number of Subjects Who Are Nausea Free at the 2-hour Assessment
Number of subjects who are nausea free at the 2-hour assessment
Time frame: 2 hours
Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment.
Number of subjects who are free of photophobia at the 2-hour assessment.
Time frame: 2 hours
Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment.
Number of subjects who are free of phonophobia at the 2-hour assessment.
Time frame: 2 hours
| Milestone | Placebo | Acetaminophen 250 mg and Aspirin 250 mg |
|---|---|---|
| Started | 453 | 447 |
| Completed | 423 | 425 |
| Not completed | 30 | 22 |
Number of subjects who are pain free at the 2-hour assessment
| participants | Placebo | Acetaminophen 250 mg and Aspirin 250 mg |
|---|---|---|
| Number of Subjects Who Are Pain Free at the 2-hour Assessment | 69 | 90 |
Number of subjects who are nausea free at the 2-hour assessment
| participants | Placebo | Acetaminophen 250 mg and Aspirin 250 mg |
|---|---|---|
| Number of Subjects Who Are Nausea Free at the 2-hour Assessment | 208 | 244 |
Number of subjects who are free of photophobia at the 2-hour assessment.
| participants | Placebo | Acetaminophen 250 mg and Aspirin 250 mg |
|---|---|---|
| Number of Subjects Who Are Free of Photophobia at the 2-hour Assessment. | 116 | 127 |
Number of subjects who are free of phonophobia at the 2-hour assessment.
| participants | Placebo | Acetaminophen 250 mg and Aspirin 250 mg |
|---|---|---|
| Number of Subjects Who Are Free of Phonophobia at the 2-hour Assessment. | 142 | 164 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/415 (0%) | 0/415 (0%) |
| Acetaminophen 250 mg and Aspirin 250 mg | — | 1/408 (0.2%) | 0/408 (0%) |
| Event | Placebo | Acetaminophen 250 mg and Aspirin 250 mg |
|---|---|---|
| intraductal profilerative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/415 | 1/408 |
| Age, Continuous(years) | Placebo | Acetaminophen 250 mg and Aspirin 250 mg | Total |
|---|---|---|---|
| Mean | 40.6 ± 12.4 | 39.7 ± 12.8 | 40.1 ± 12.6 |
| Sex: Female, Male(Participants) | Placebo | Acetaminophen 250 mg and Aspirin 250 mg | Total |
|---|---|---|---|
| Female | 351 | 350 | 701 |
| Male | 102 | 97 | 199 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Acetaminophen 250 mg and Aspirin 250 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 48 | 48 | 96 |
| Not Hispanic or Latino | 405 | 399 | 804 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Acetaminophen 250 mg and Aspirin 250 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 5 | 5 | 10 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 96 | 105 | 201 |
| White | 337 | 318 | 655 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 18 | 31 |
| Region of Enrollment(participants) | Placebo | Acetaminophen 250 mg and Aspirin 250 mg | Total |
|---|---|---|---|
| United States | 453 | 447 | 900 |
The record gives a start of Oct 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen